Company: SION
Filing Date: 2025-02-07
Form Type: 424B4
Source: 0001193125-25-022709
Chunk: 49

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-02-07
Form: 424B4
Chunk 49
---
 we are unable to develop other product candidates at the time of such termination, it would have a material adverse effect on our business, financial condition, results of operations and prospects, including, but not limited to, cessation of our operations. See “ Business—License and Collaboration Agreements” for a description of our license agreements. As we have done previously, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our current product candidates or future products in the absence of such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive,thereby giving our competitors access to the same intellectual property licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement intellectual property. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:

| • |     | the scope of rights granted under the license agreement and other interpretation-related issues; |

37

| • |     | whether and the extent to which our product candidates and processes infringe on intellectual property of the licensor that 
 is not subject to the licensing agreement;                                                                                  |

| • |     | our right to sublicense patent and other rights to third parties under collaborative development relationships; |

| • |     | our diligence obligations with respect to the use of the licensed intellectual property in relation to our development and 
 commercialization of our product candidates, and what activities satisfy those diligence obligations; and                  |

| • |     | the ownership of inventions and know-how resulting from the joint creation or use 
 of intellectual property by our licensors and us and our partners.                |

If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. We currently rely on, and